40987-25-5

Usage

Uses

Used in Pharmaceutical Research and Development:
4-Benzyl-2-(Chloromethyl)morpholine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a valuable building block in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, 4-Benzyl-2-(Chloromethyl)morpholine is employed as a reagent in various chemical reactions. Its chloromethyl group can participate in nucleophilic substitution reactions, making it a useful component in the synthesis of complex organic molecules.
Used in Material Science:
4-Benzyl-2-(Chloromethyl)morpholine may also find applications in material science, where its unique properties can be utilized to develop new materials with specific characteristics. Its potential use in this field is still under exploration and may lead to innovative applications in the future.

InChI:InChI=1/C12H16ClNO/c13-8-12-10-14(6-7-15-12)9-11-4-2-1-3-5-11/h1-5,12H,6-10H2/p+1/t12-/m1/s1

Upstream product

• 174560-84-0 1-chloro-3-[(2-hydroxyethyl)(phenylmethyl)amino]-2-propanol 
• 104-63-2 N-Benzylethanolamine 
• 106-89-8 epichlorohydrin 
• 100-52-7 benzaldehyde 

Downstream Products

• 110859-48-8 N-[(4-benzyl-2-morpholinyl)methyl]phthalimide 
• 57962-45-5 (4-benzylmorpholin-2-yl)acetonitrile 
• 40987-24-4 R,S-2-hydroxymethyl-4-benzylmorpholine 
• 112913-97-0 2-(azidomethyl)-4-benzylmorpholine 
• 47374-79-8 (+/-)-4-benzyl-2-(2-ethoxyphenoxymethyl)morpholine 
• 126645-75-8 4-benzyl-2-<(methylamino)methyl>morpholine 
• 146944-34-5 (4-benzylmorpholin-2-ylmethyl)carbamic acid tert-butyl ester 
• 143804-53-9 4-benzyl-2-(methoxymethyl)morpholine 
• 132995-54-1 ethyl 4-[[4-(phenylmethyl)-2-morpholinyl]methoxy]benzoate (E)-2-butenedioate 
• 118976-27-5 R,S-8-[(4-benzyl-2-morpholinyl)methoxy]-1,2,3,4-tetrahydroquinoline 
• 635699-06-8 4-benzyl-2-(pyrrolidin-1-ylmethyl)morpholine 
• 1010835-07-0 6-[1-(4-Benzylmorpholin-2-ylmethyl)-2-tert-butyl-1H-imidazol-4-yl]-N-methyl-N-propylpyrazine-2-carboxamide 
• 146944-27-6 4-benzylmorpholine-2-acetic acid 
• 766539-34-8 methyl 2-(4-benzylmorpholine-2-yl)acetate 

Relevant academic research and scientific papers

Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer

The enzyme butyrylcholinesterase (BChE) represents a promising target for imaging probes to potentially enable early diagnosis of neurodegenerative diseases like Alzheimer's disease (AD) and to monitor disease progression in some forms of cancer. In this study, we present the design, facile synthesis, in vitro and preliminary ex vivo and in vivo evaluation of a morpholine-based, selective inhibitor of human BChE as a positron emission tomography (PET) tracer with a pseudo-irreversible binding mode. We demonstrate a novel protecting group strategy for 18F radiolabeling of carbamate precursors and show that the inhibitory potency as well as kinetic properties of our unlabeled reference compound were retained in comparison to the parent compound. In particular, the prolonged duration of enzyme inhibition of such a morpholinocarbamate motivated us to design a PET tracer, possibly enabling a precise mapping of BChE distribution.

INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS

The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists

Fast and efficient 18F-labeling by [18F]fluorophenylazocarboxylic esters

Introduction of [18F]fluoride ion into the aromatic core of phenylazocarboxylic esters was achieved in only 30 seconds, with radiochemical yields of up to 95% (85(±10) %). For labeling purposes, the resulting 18F-substituted azoester can be further converted in radical-arylation reactions to give biaryls, or in substitutions at its carbonyl unit to produce azocarboxamides.

NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS

The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors.

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

Concise synthesis of (S)-N-BOC-2-hydroxymethylmorpholine and (S)-N-BOC-morpholine-2-carboxylic acid

(Chemical Equation Presented) An operationally simple synthesis of N-BOC-2-hydroxymethylmorpholine (1) and N-BOC-morpholine-2-carboxylic acid (2) from epichlorohydrin has been developed. No chromatography is required in the processing, which allows high p

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine D4 receptor antagonists

The present invention relates to compounds of formula (I), any of it enantiomers, or any mixture thereof, or a pharmaceutically acceptable acid addition salt thereof, wherein R1, R2, R3, R4, R11, R12, R13, R14and R15each independently are hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, nitro, cyano, amino, acyl, alkylamino, dialkylamino, aminocarbonyl, or acylamino; R5 is hydrogen, alkyl, alkoxyalkyl, or phenylalkyl; X is —CH2—Z—, Z—CH2—, NH—CO—, —CO—NH—, or —CH═CH—; wherein Z is O, S, CH2, or NH; Y is O, —CH2—W—, —W—CH2—; wherein W is O, or S; and n is 0, 1 or 2. The compounds are useful in the treatment of psychotic disorders.

Pyrimidine derivatives

Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula STR1 wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1 -C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1 -C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1 -C6 alkyl group, a C3 -C6 cycloalkyl group, an aryl group or the like; R4 is --SR7 or --NR8 R9 wherein R7 is a C1 -C6 alkyl group; R8 is a C1 -C6 alkyl group or the like; R9 is a hydrogen atom, a C1 -C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) STR2 wherein R10 represents a C1 -C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.